{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:42:25Z","timestamp":1793065345285,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmoop.2026.108360","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:12:20Z","timestamp":1787141540000},"page":"108360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating tumor DNA dynamics in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assay"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-9167","authenticated-orcid":false,"given":"C.H.","family":"Barcenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3837-6471","authenticated-orcid":false,"given":"C.W.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-0511","authenticated-orcid":false,"given":"K.C.","family":"Keough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2842-4476","authenticated-orcid":false,"given":"R.O.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-2404","authenticated-orcid":false,"given":"D.","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108360_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2026.108360_bib2","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108360_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/CCI.21.00020","article-title":"Prognostic model for de novo and recurrent metastatic breast cancer","volume":"5","author":"Barcenas","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.esmoop.2026.108360_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib5","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.21037\/tcr-2025-40","article-title":"Liquid biopsy in advanced and metastatic breast cancer: translating prognostic value to clinical implementation","volume":"14","author":"Goodman","year":"2025","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108360_bib6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s41467-022-29487-y","article-title":"Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling","volume":"13","author":"Wu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108360_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1470-2045(12)70209-7","article-title":"Circulating tumour cells in non-metastatic breast cancer: a prospective study","volume":"13","author":"Lucci","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.esmoop.2026.108360_bib10","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.15252\/emmm.201404913","article-title":"Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease","volume":"7","author":"Olsson","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.esmoop.2026.108360_bib12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.22.00908","article-title":"Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer","volume":"40","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2026.108360_bib14","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1186\/s12885-024-12689-6","article-title":"Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2026.108360_bib15","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2026.108360_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib17","article-title":"Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse","volume":"6","author":"Cailleux","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-026-00904-5","article-title":"Dynamic biomarkers in hormone receptor-positive\/HER2-negative breast cancer trials: a new hope for precision oncology","volume":"12","author":"Di Grazia","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.108360_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.18632\/oncotarget.28565","article-title":"Analytical validation of NeXT Personal(R), an ultra-sensitive personalized circulating tumor DNA assay","volume":"15","author":"Northcott","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2026.108360_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.annonc.2025.01.021","article-title":"Whole genome sequencing-powered ctDNA sequencing for breast cancer detection","volume":"36","author":"Garcia-Murillas","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2026.108360_bib23","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.esmoop.2026.108360_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.esmoop.2026.108360_bib25","article-title":"Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+\/HER2\u2212 early breast cancer","volume":"81","author":"O\u2019Shaughnessy","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.esmoop.2026.108360_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.esmoop.2026.108360_bib27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41416-022-01776-9","article-title":"Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges","volume":"127","author":"Garc\u00eda-Pardo","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108360_bib28","article-title":"Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer","volume":"8","author":"Shaw","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2026.108360_bib29","article-title":"Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy in HR+, HER2\u2212, node-positive, high-risk early breast cancer","volume":"42","author":"Loi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108360_bib30","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-23-0757","article-title":"Molecular residual disease in breast cancer: detection and therapeutic interception","volume":"29","author":"Medford","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108360_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.clbc.2023.06.008","article-title":"Circulating tumor DNA in breast cancer: current and future applications","volume":"23","author":"Medford","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.esmoop.2026.108360_bib32","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14737140.2026.2630023","article-title":"The clinical utility of molecular residual disease testing in early-stage breast cancer","volume":"26","author":"Micha","year":"2026","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.esmoop.2026.108360_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331203","article-title":"The SURVIVE study (NCT05658172): bringing breast cancer aftercare to the 21st century: study protocol of a phase III clinical trial comparing liquid biopsy-guided vs. standard-of-care surveillance for intermediate to high-risk breast cancer survivors","volume":"20","author":"Braun","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.108360_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0322156","article-title":"Study protocol of SURVIVE HERoes (NCT06643585): trastuzumab deruxtecan for molecular relapse in HER2+\/low early breast cancer with ctDNA positivity after primary therapy","volume":"20","author":"Pfister","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2026.108360_bib35","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II\u2014binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926023033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926023033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:40:04Z","timestamp":1792770004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926023033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2059702926023033"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108360","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA dynamics in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assay","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108360"}}